Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Cytokinetics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 564

Market Cap: $6.5B

Website

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 3

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Reldesemtiv
Drug: Placebo

First Posted Date: 2021-06-30

Last Posted Date: 2024-12-05

Lead Sponsor: Cytokinetics

Target Recruit Count: 489

Registration Number: NCT04944784

Locations: 🇺🇸
St. Joseph's Hospital & Medical Center - Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of California Irvine - ALS & Neuromuscular Center, Orange, California, United States

and more 81 locations

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Phase 2

Conditions: Symptomatic Hypertrophic Cardiomyopathy (HCM)

Interventions: Drug: Aficamten (5 - 20 mg)

First Posted Date: 2021-04-19

Last Posted Date: 2025-06-04

Lead Sponsor: Cytokinetics

Target Recruit Count: 900

Registration Number: NCT04848506

Locations: 🇺🇸
Alaska Heart and Vascular Institute, Anchorage, Alaska, United States
🇺🇸
Mayo Clinic Building - Phoenix, Phoenix, Arizona, United States
🇺🇸
UC San Diego Health - Sulpizio Cardiovascular Center, La Jolla, California, United States

and more 87 locations

Omecamtiv Mecarbil Post-trial Access Study

Phase 3

Withdrawn

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Omecamtiv mecarbil

First Posted Date: 2020-07-09

Last Posted Date: 2021-07-30

Lead Sponsor: Cytokinetics

Registration Number: NCT04464525

Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM

Phase 2

Completed

Conditions: Hypertrophic Cardiomyopathy (HCM)

Interventions: Drug: CK-3773274 (5 - 15 mg)
Drug: CK-3773274 (10 - 30 mg)
Drug: Placebo for CK-3773274

First Posted Date: 2020-01-07

Last Posted Date: 2025-03-25

Lead Sponsor: Cytokinetics

Target Recruit Count: 96

Registration Number: NCT04219826

Locations: 🇺🇸
Cedar-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
UCSF Medical Center, San Francisco, California, United States
🇺🇸
Northwestern University, Evanston, Illinois, United States

and more 19 locations

Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults

Phase 1

Completed

Conditions: QT Intervals Changes
QTc Intervals Changes

Interventions: Drug: Omecamtiv Mecarbil (OM)
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2019-11-25

Last Posted Date: 2025-03-30

Lead Sponsor: Cytokinetics

Target Recruit Count: 70

Registration Number: NCT04175808

Locations: 🇬🇧
Research Site, Leeds, United Kingdom

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Subjects
Symptomatic Obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: Placebo - Granules in Capsule
Drug: CK-3773274 - Granules in Capsule
Drug: CK-3773274 - Tablets

First Posted Date: 2018-12-07

Last Posted Date: 2025-01-24

Lead Sponsor: Cytokinetics

Target Recruit Count: 114

Registration Number: NCT03767855

Locations: 🇺🇸
Clinical Site, Tempe, Arizona, United States

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

Phase 3

Completed

Conditions: Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Omecamtiv Mecarbil
Drug: Placebo

First Posted Date: 2018-11-30

Last Posted Date: 2023-03-07

Lead Sponsor: Cytokinetics

Target Recruit Count: 276

Registration Number: NCT03759392

Locations: 🇺🇸
Alaska Heart and Vascular Institute, Anchorage, Alaska, United States
🇺🇸
Arkansas Cardiology Clinic, Little Rock, Arkansas, United States
🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States

and more 78 locations

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Reldesemtiv
Drug: Placebo

First Posted Date: 2017-05-19

Last Posted Date: 2020-09-11

Lead Sponsor: Cytokinetics

Target Recruit Count: 458

Registration Number: NCT03160898

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center - Barrow Neurological Clinics, Phoenix, Arizona, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of California Irvine, Orange, California, United States

and more 60 locations

A Study for Patients Who Completed VITALITY-ALS (CY 4031)

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Interventions: Drug: tirasemtiv

First Posted Date: 2016-10-18

Last Posted Date: 2021-06-15

Lead Sponsor: Cytokinetics

Target Recruit Count: 280

Registration Number: NCT02936635

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center - Barrow Neurology Clinics, Phoenix, Arizona, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of California, Irvine, Orange, California, United States

and more 64 locations

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Omecamtiv Mecarbil
Drug: Placebo
Drug: Standard of Care

First Posted Date: 2016-10-11

Last Posted Date: 2021-11-05

Lead Sponsor: Cytokinetics

Target Recruit Count: 8256

Registration Number: NCT02929329

Locations: 🇬🇧
Research Site, Worcester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy